Activation of GLP-1R by GLP-1 or other exogenous agonists, including exendin-4 and liraglutide, decreases inflammatory responses in several animal models like rat heart and whole animal model
David Henry - beneficios riesgos GLP1 EN David Henry Honorary Adjunct Professor in the Faculty of Science and Medicine at the Institute for Evidence-Based Healthcare at Bond University, University of NSW and University of Melbourne The paper describes a data-driven approach to studying possible beneficial and adverse effects of GLP-1 agonists like semaglutide (Ozempic), which are widely used to treat diabetes and obesity
Market demand for GLP-1s could be sizable and enduring over the long term, presenting an opportunity for smaller businesses
Still, more long-term, large-scale, multiethnic, phenotype-specific, well-designed trials are warranted to confirm the efficacy and safety of GLP-1s in preconception PCOS women. GLP-1 receptors are present in the ovaries, endometrium, and testes